EnVivo Pharmaceuticals, Inc. Announces Positive Phase 2b Clinical Data in Schizophrenia: EVP-6124 Meets Primary Endpoint with Statistically Significant Improvement in Cognition and Multiple Secondary Endpoints for Improvement in Function and Impact on Negative Symptoms

5/17/2011 10:42:05 AM

WATERTOWN, Mass.--(BUSINESS WIRE)--EnVivo Pharmaceuticals announced today positive topline results of its randomized, placebo-controlled Phase 2b clinical trial of EVP-6124, its potent, orally bioavailable and selective alpha-7 agonist, in patients with schizophrenia. The data showed that EVP-6124 had a clinically meaningful and statistically significant impact on patients’ overall cognition - the trial’s pre-specified primary endpoint - when taken in combination with second-generation antipsychotics and as measured by the full CogState overall cognitive index, or “OCI” (p=0.05 for all patients treated with EVP-6124 versus placebo.) This positive effect on the OCI was supported by a strong positive trend for improved cognition on the MCCB Battery of cognition tests, which were conducted on all U.S. patients in the trial.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• EnVivo Pharmaceuticals, Inc.

• Clinical - Phase II